Fibroblast Growth Factor-23 and Parathyroid Hormone Are Associated with Post-Transplant Bone Mineral Density Loss | Zendy

Nada Kanaan | Zendy; Kathleen Claes | Zendy; JeanPierre Devogelaer | Zendy; Dirk Vanderschueren | Zendy; Geneviève Depresseux | Zendy; Éric Goffin | Zendy; Pieter Evenepoel | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Fibroblast Growth Factor-23 and Parathyroid Hormone Are Associated with Post-Transplant Bone Mineral Density Loss

Author(s) -

Nada Kanaan,

Kathleen Claes,

JeanPierre Devogelaer,

Dirk Vanderschueren,

Geneviève Depresseux,

Éric Goffin,

Pieter Evenepoel

Publication year - 2010

Publication title -

clinical journal of the american society of nephrology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.755

H-Index - 151

eISSN - 1555-905X

pISSN - 1555-9041

DOI - 10.2215/cjn.00950110

Subject(s) - medicine , bone mineral , fibroblast growth factor 23 , parathyroid hormone , endocrinology , bone density , fibroblast growth factor , urology , osteoporosis , calcium , receptor

Among the multiple factors contributing to bone mineral density (BMD) loss after renal transplantation, hypophosphatemia is increasingly recognized to play an important role. Hypophosphatemia occurs in up to 90% of the renal transplant recipients in the early post-transplant period and is caused by renal phosphate wasting. We hypothesized that a high pretransplant level of the recently described phosphaturic hormone fibroblast growth factor 23 (FGF-23) is a risk factor for accelerated BMD loss occurring within the first post-transplant year.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research